Morning Market Losers

ImmunoCellular Therapeutics IMUC dropped 59.85% to $1.09 after the company announced positive ICT-107 Phase II study results. Roth Capital downgraded the stock from Buy to Neutral. Synthetic Biologics SYN plummeted 22.06% to $0.99 after the company priced 11.5 million shares of common stock at $1.00. XTL Biopharmaceuticals XTLB dropped 17% to $2.49. XTL Biopharmaceuticals shares have dropped 60.00% over the past 52 weeks, while the S&P 500 index has gained 25.56% in the same period. Sigma Designs SIGM dropped 16.82% to $4.45 on Q3 results. Needham downgraded the stock from Buy to Hold.